BROSSARD, QUEBEC--(Marketwired - June 8, 2016) - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), an innovative leader in healthcare technical services, including screening software and algorithm development, data analysis, and image processing, announces today a contract award for a strategic initiative in Latin America to screen a large population of diabetics by December 31, 2016. Under the final agreement, it is expected that DIAGNOS will receive a 40% deposit on the total amount and a monthly payment until December 31, 2016. DIAGNOS is working closely with the customer to identify the requirements for an additional two years of services.
According to the International Diabetes Federation, this country, ranked 6th worldwide in number of people with diabetes, second in adult obesity, and first in child obesity, is taking the lead to reverse these unfavorable health trends by investing in prevention and education.
In the last 20 years, the client has spent more than US$1.2 billion treating complications from diabetes which could have been avoided by implementing wellness programs. Blindness is one major complication that has a huge impact on our families and society. The objective is now to unburden the economic load by preventing up to 85% of blindness cases and delivering an accessible service of the highest quality.
"Our commitment is to assist the National Diabetes Program via a mass screening project aimed at reducing the cost of diabetes and preventing vision loss in its population. After four years of experience deploying screening projects in many countries including India, UAE, Algeria, Poland, Canada, USA, Colombia, Mexico, we're highly committed to adding value to this program by offering comprehensive services. The uniqueness the DIAGNOS technology platform "CARA" (Computer Assisted Retinal Analysis) in terms of image processing and enhancement enables for faster referral to specialists," said Mr. André Larente, President of DIAGNOS.
About DIAGNOS
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.
About CARA
CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, and the European Union.
Forward-looking information
This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these
statements.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information:
1-877-678-8882 or (450) 678-8882, ext.: 224
alarente@diagnos.ca